Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in HPV-positive Oropharyngeal Cancer
NCT07513324Phase 2Withdrawn
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Dec 2026
- Primary completion
- Jan 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of pembrolizumab in oropharyngeal squamous cell carcinoma (OPSCC), sponsored by Dana-Farber Cancer Institute. Planned start Dec 2026; status: withdrawn.
02
Drugs
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT07513324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07513324.